# A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

Source: https://onco.cc/trials/nct07743112/  
OnCo record `nct07743112` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Azacitidine and Venetoclax in acute myeloid leukaemia, run by Maxinovel Pty., Ltd., now recruiting.

## Summary

A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia is a phase 2 interventional study registered as NCT07743112 by Maxinovel Pty., Ltd., with 43 participants planned, started 2025-09-05 and due to reach its primary completion in 2027-09-01. Interventions recorded: MAX-40279, Azacitidine and Venetoclax.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07743112
- Phase: 2
- Setting: A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
- Sponsor: Maxinovel Pty., Ltd.
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT07743112: https://clinicaltrials.gov/study/NCT07743112

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- drugs: [Azacitidine](https://onco.cc/drugs/azacitidine/), [Venetoclax](https://onco.cc/drugs/venetoclax/)

---
JSON: https://onco.cc/api/v1/entities/nct07743112.json